Amy J. Davidoff, PhD

Articles by Amy J. Davidoff, PhD

Utilization Impacts of New Oral Substitutes for Parenteral Cancer-Related Therapies

ByAmy J. Davidoff, PhD,Amer Zeidan, MD,Franklin Hendrick, BS,Bruce C. Stuart, PhD,Vu H. Duong, MD, MS,Maria R. Baer, MD,Rahul A. Shenolikar, PhD,Steven D. Gore, MD

March 17th 2015

Examination of changes in utilization, dose adequacy, and duration associated with market entry of the oral chelator deferasirox as a potential substitute for parenteral deferoxamine.

Latest Updated Articles

Utilization Impacts of New Oral Substitutes for Parenteral Cancer-Related Therapies
Published: March 17th 2015 | Updated:

Amy J. Davidoff, PhD

Articles by Amy J. Davidoff, PhD

Utilization Impacts of New Oral Substitutes for Parenteral Cancer-Related Therapies

Latest Updated Articles

Trending on Pharmacy Times

Ban Synthetic 7-OH: Natural Leaf Kratom Presents No Major Health Risk

Pharmacists Key to Counseling and Monitoring Patients Transitioning to Low-Sodium Oxybate